Trial Profile
A Phase III, Randomized, Double-blind, Three-arm, Placebo-controlled, Multi-center Study to Evaluate the Safety and Efficacy of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Dec 2023
Price :
$35
*
At a glance
- Drugs Cladribine (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CLARITY
- Sponsors EMD Serono; Merck Serono
- 13 Oct 2023 Results of a retrospective longitudinal study assessing neuroprotective effect of treatment with cladribine tablets compared to placebo on MRI-derived patterns of atrophy relapsing-remitting multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 26 Dec 2022 Results of a post-hoc analysis assessing the GM and WM volume changes, using a robust longitudinal method, in patients with relapsing MS randomized to cladribine tablets 3.5 mg/kg or placebo in the CLARITY study, published in the European Journal of Neurology
- 01 Jan 2022 Results of post-hoc analysis frequency and severity of relapses in patients treated with CladT versus placebo (CLARITY & CLARITY EXT) were published in the Multiple Sclerosis Journal.